On February 17, the management department of gem company of Shenzhen Stock Exchange issued a letter of concern to Hybio Pharmaceutical Co.Ltd(300199) , requesting to explain the current research and development stage of covid-19 polypeptide nasal spray project, research and development investment, research and development investment required in the future and research and development steps to be carried out, In combination with the company's capital and debt situation, fully explain whether the company's capital is sufficient to support the R & D of covid-19 polypeptide nasal spray project, and fully prompt the risks in combination with the R & D progress and R & D investment of comparable companies, market competition pattern, uncertainty faced in the R & D process, etc.
© China Stock Market News